Information

Target Indication: Acromegaly Gastroenteropancreatic Neuroendocrine Tumors Carcinoid Syndrome  Strength:60mg, 90mg, 120mg  Formulation:Injection/PFS Timetable: Process Validation in Q3. 2026 ANDA will be submitted in Q2. 2027 in US

Log in

See all the content and easy-to-use features by logging in or registering!